Low-grade systemic inflammation and left ventricular dysfunction in hypertensive compared to non-hypertensive hypertrophic cardiomyopathy
Authors:
Open Access
- 27 December 2023
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 399, 131661
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Inc
- Boehringer Ingelheim Pharma GmbH und Co. KG
- Takeda Pharmaceutical Co Ltd
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Co
- Austrian Society of Cardiology
This publication has 38 references indexed in Scilit:
- Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant HypertensionJACC, 2012
- The Progression of Hypertensive Heart DiseaseCirculation, 2011
- Interleukin 6 Knockout Prevents Angiotensin II HypertensionHypertension, 2010
- The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA)Journal of Human Hypertension, 2010
- Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative StressCirculation, 2007
- Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjectsJournal of Human Hypertension, 2005
- Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertensionJournal of Human Hypertension, 2004
- The Molecular Genetic Basis for Hypertrophic CardiomyopathyJournal of Molecular and Cellular Cardiology, 2001
- Raised Interleukin‐6 Levels in Obese PatientsObesity Research, 2000
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986